secwatch.observer — SEC 8-K summary
======================================

Issuer:     Horizon Therapeutics Public Ltd Co (—)
CIK:        0001492426
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0001193125-23-252368
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.02, 2.01, 5.01, 3.01, 3.03, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen completes $26.7B acquisition of Horizon Therapeutics; shares delisted
---------------------------------------------------------------------------

- Horizon shareholders received $116.50 per share in cash; aggregate consideration ~$26.7B.
- Horizon repaid $1.982B credit facility and deposited $622.8M to redeem 5.500% Senior Notes due 2027.
- Horizon requested delisting from Nasdaq; Form 25 filed; intends to file Form 15 to suspend reporting.
- All directors (Timothy Walbert, Michael Grey, etc.) resigned; board replaced by Amgen designees.
- Amended and restated Memorandum and Articles of Association effective at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492426/000119312523252368/0001193125-23-252368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492426/000119312523252368/d516584d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-252368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer